Predictive Oncology (NASDAQ: POAI) closes 2 private placements, adopts digital asset strategy

Rhea-AI Filing Summary

Predictive Oncology Inc. filed an 8-K describing a press release issued on October 8, 2025. The release announced the closing of two private placements on October 7, 2025 and the company’s adoption of a digital asset treasury strategy, signaling a change in how it may hold part of its treasury assets. The press release is furnished under Regulation FD and attached as Exhibit 99.1, with most of its content (excluding the fifth and sixth paragraphs) also treated as an “Other Event” disclosure.

False000144615900014461592025-10-072025-10-07iso4217:USDxbrli:sharesiso4217:USDxbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

_________________

FORM 8-K

_________________

CURRENT REPORT

Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):  October 7, 2025

_______________________________

Predictive Oncology Inc.

(Exact name of registrant as specified in its charter)

_______________________________

Delaware	001-36790	33-1007393
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

91 43rd Street, Suite 110

Pittsburgh, Pennsylvania 15201

(Address of Principal Executive Offices) (Zip Code)

(412) 432-1500

(Registrant's telephone number, including area code)

(Former name or former address, if changed since last report)

_______________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common stock, $0.01 par value	POAI	Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01. Regulation FD Disclosure.

On October 8, 2025, Predictive Oncology Inc. issued a press release announcing the closing of two private placements on October 7, 2025 and its adoption of a digital asset treasury strategy.

The press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated into this Item 7.01 by reference. The information in this Item 7.01, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”), as amended, or otherwise subject to the liabilities of that section, nor shall they be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 8.01. Other Events.

The information set forth in the press release referred to in Item 7.01 above, other than the fifth and sixth paragraphs thereof, is incorporated by reference into this Item 8.01 of this Current Report on Form 8-K.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description of Exhibit
99.1		Press Release, dated October 8, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Predictive Oncology Inc.
Date: October 8, 2025	By:	/s/ Josh Blacher
		Josh Blacher
		Interim Chief Financial Officer

FAQ

What did Predictive Oncology (POAI) disclose in this 8-K filing?

Predictive Oncology disclosed that it issued a press release on October 8, 2025 announcing the closing of two private placements on October 7, 2025 and its adoption of a digital asset treasury strategy.

When did Predictive Oncology (POAI) close the private placements?

The company reported that the two private placements closed on October 7, 2025.

What is the digital asset treasury strategy mentioned by Predictive Oncology (POAI)?

The company stated that it has adopted a digital asset treasury strategy, indicating a plan to manage part of its treasury using digital assets, as described in the attached press release.

Which exhibit in the 8-K contains details on the private placements and digital asset strategy?

Exhibit 99.1, a press release dated October 8, 2025, contains the detailed information on the two private placements and the digital asset treasury strategy.

How is the press release information treated under securities laws in this Predictive Oncology (POAI) 8-K?

The information in Item 7.01, including Exhibit 99.1, is furnished under Regulation FD and is not deemed filed for purposes of Section 18 of the Exchange Act, nor automatically incorporated into other Securities Act or Exchange Act filings.

Which parts of the press release are incorporated into Item 8.01 for Predictive Oncology (POAI)?

All information in the press release referenced in Item 7.01, other than the fifth and sixth paragraphs, is incorporated by reference into Item 8.01 as an Other Event disclosure.